-
Guotan Pharmaceutical "Dual Channel" Management Adjustment!
Time of Update: 2022-05-15
The second is to transfer Eltrombopag ethanolamine tablets in the national medical insurance negotiation drug list to the "dual-channel" management and separate payment list .
-
Chia Tai Tianqing enters Bayer's 1 billion contrast agent and competes with Chengdu Bite for the first imitation
Time of Update: 2022-05-15
Figure 1: The latest product status of Chia Tai Tianqing Pharmaceutical Group Source: CDE official website Figure 2: Bayer's sales of iopromide (unit: 100 million yuan) Source: Minet.
Figure 3: Sources of contrast agents approved by Chia Tai Tianqing Pharmaceutical Group: The new version database of Minet.
-
16.3 billion anti-allergic drug market business opportunities are "sensitive"
Time of Update: 2022-05-15
From the perspective of enterprises, there will be 181 manufacturers selling antiallergic drugs in the sample hospitals in 2021, of which the sales of Yangzijiang Pharmaceutical Group (including 4 subsidiaries) will account for 29.
-
Coron will win the $1.5 billion big variety!
Time of Update: 2022-05-15
Recently, Kelun Pharmaceutical entered the administrative examination and approval stage with the imitation of Class 3 Sodium Glucose Injection, which is the second domestic company .
According to the first quarterly report of 2022, Kelun Pharmaceutical's net profit increased by 66.
-
Grasp the new blue ocean of the big health industry to promote economic growth and overtake
Time of Update: 2022-05-15
Since March 2022, a new round of COVID-19 has spread, and China's economic development has been greatly impacted, greatly increasing the downside risks of the macro economy . Coordinating and balan
-
Cases of severe acute hepatitis of unknown etiology in children continue to increase in Europe
Time of Update: 2022-05-15
(Headquarters reporter Hao Xiaoli) On April 28, local time, the European Centre for Disease Control and Prevention issued a statement that, as of April 20, 111 cases of severe acute hepatitis of unknown etiology had been identified in the UK as of April 20, after the UK first reported an increase in cases of severe acute hepatitis of unknown etiology among healthy children on April 5.
-
Xiebai relies on wild resources, and the market outlook is expected to rise slowly!
Time of Update: 2022-05-15
To sum up, as of now, the new output of Xiebai is limited, and the labor cost of harvesting and processing has increased, so the market price may rise in the future .
-
CDC: Adenovirus may be the cause of some childhood hepatitis of unknown etiology
Time of Update: 2022-05-14
According to a report released by the US Centers for Disease Control and Prevention on April 29, between October 2021 and February 2022, a total of 9 cases of acute hepatitis of unknown etiology in children with unknown etiology were reported in Alabama, USA, and none of these cases had a history of new crown infection.
-
Cancer Prevention Awareness Week: Microwave Ablation Helps Minimally Invasive Treatment of Tumors
Time of Update: 2022-05-13
In recent years, the development trend of tumor treatment technology in China has been blowout: the treatment methods are constantly enriched, the treatment level is constantly improved, the treatment effect is getting better and better, and the survival period of tumor patients is getting longer and longer, and tumor treatment has entered a new stage of development since then.
-
See how Shante's "prescription" "cures" the "stubborn disease" in the construction of medical informatization
Time of Update: 2022-05-12
Sand Castle series 0-200kVA UPS, through more than 30 years of experience accumulation and advanced digital control technology, further improve the reliability and adaptability of products, and meet the needs of users in the medical industry for power safety and centralized management .
-
A number of chain cancellations have intensified competition in the pharmacy market
Time of Update: 2022-05-11
[Pharmaceutical Network Market Analysis] Recently, the Hubei Provincial Food and Drug Administration issued an announcement stating that according to relevant regulations, the enterprise decided to cancel the "Drug Business License" of Hubei Yifeng Alkang Pharmacy Chain Co.
-
The pharmaceutical manufacturing industry grew by nearly 13% in the first two months, and it is expected to continue to develop rapidly throughout the year
Time of Update: 2022-05-11
The data shows that from January to February 2022, the added value of China's pharmaceutical manufacturing industry will maintain double-digit growth, with a year-on-year increase of nearly 13%, a growth rate higher than the national industry 5.
-
Sprinting for A+H listing, raising more than 12.5 billion yuan, this week's IPO pharmaceutical companies are concerned
Time of Update: 2022-05-11
According to the prospectus, Nuocheng Jianhua plans to raise 4 billion yuan on the Science and Technology Innovation Board for new drug research and development projects, drug research and development platform upgrade projects, marketing network construction projects, informatization construction projects and supplementary working capital .
-
The prosperity of the innovative drug industry is gradually heating up, and pharmaceutical companies are accelerating their efforts to the field of FIC research and development
Time of Update: 2022-05-11
R&D investment has continued to increase, and at the same time, a large number of companies have actively introduced clinical-stage products through authorized cooperation, resulting in the continuous emergence of first-in-class and fast-follower drugs in the domestic market .
-
10 executives "leave the field" within 10 months, what is this multinational pharmaceutical company doing?
Time of Update: 2022-05-11
. From the perspective of the reasons, the main reason is that the new medical reform policies such as medical insurance negotiation and centralized procurement implemented in China in recent years have had an impact on the company's performance .
-
Shares of these pharmaceutical stocks hit a one-year high
Time of Update: 2022-05-11
[Pharmaceutical Network Pharmaceutical Stock Market] According to data from Flush, as of April 12, 2022, the stock prices of many pharmaceutical stocks such as Kangyuan Pharmaceutical, China Resources Shuanghe, Dali Pharmaceutical, and First Medicine have reached a new high in one year .
-
Traditional Chinese medicine is expected to usher in a new round of development opportunities, and many pharmaceutical companies have locked in expectations for performance growth in the first quarter
Time of Update: 2022-05-11
Pien Tze Huang recently released the 2022 first quarter performance forecast, showing that the company expects a pre-increase in the first quarter of 2022, and the net profit attributable to shareholders of listed companies will increase by 20% to 24% year-on-year, to 678 million to 701 million yuan .
-
The science and technology innovation board index system continues to improve, becoming an important listing place for biopharmaceutical companies
Time of Update: 2022-05-11
Analysts pointed out that the current listed biopharmaceutical companies on the Science and Technology Innovation Board have the attributes of low valuation, high growth, and high R&D, and the investment value is obvious .
-
The R&D expenses of thousands of companies have increased by more than 20%, and the pharmaceutical and biological fields account for a large proportion
Time of Update: 2022-05-11
In recent years, with the country's continuous emphasis on innovative drugs, pharmaceutical companies have begun to increase investment in research and development to achieve transformation .
-
Industry: The "bubble" of innovative drugs will burst, and a large number of Biotech companies may disappear!
Time of Update: 2022-05-11
[Pharmaceutical Network Market Analysis] In recent years, with the continuous introduction of domestic policies to support pharmaceutical innovation, China's innovative drug industry has ushered in r
